Serological Test News and Research

RSS

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

1 Apr 2011

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

31 Mar 2011

DGP/tTG Screen assay may be best initial test for suspected celiac disease: Study

Diagnosis of celiac disease is based on a characteristic enteropathy in an intestinal biopsy and evidence that these changes are gluten-triggered. The appropriate use of simpler and more accurate tools would add reliability to the diagnosis of celiac disease. Thus, the celiac disease-related serology might have a key role in defining new diagnostic standards for celiac disease.

9 Jul 2010

Asbestos induces cell necrosis, promotes tumor growth

More than 20 million people in the U.S., and many more worldwide, who have been exposed to asbestos are at risk of developing mesothelioma, a malignant cancer of the membranes that cover the lungs and abdomen that is resistant to current therapies.

30 Jun 2010

HSV-2 can reactivate throughout the genital tract

Genital herpes caused by a reactivation of herpes simplex virus type 2 (HSV-2) is generally treated as a lesion in one specific area of the genital region. A new study, however, finds that the virus can frequently reactivate throughout the genital tract, an important new concept that could help guide both HSV-2 treatment and prevention.

23 Jan 2010

Jagiellonian University to develop modern reagents for serological tests

Every year, 2 million patients in Poland are treated with blood and blood products. But only blood compatible with the recipient's blood type can be safely transfused.

1 Oct 2009

Lyme disease emerging in Canada

Lyme disease is emerging in Canada, and is expected to increase with climate change, but effective, enhanced surveillance and clinician awareness will be key to minimizing the impact of the disease, write researchers in a review in CMAJ (Canadian Medical Association Journal).

9 Jun 2009

CSL Behring receives FDA approval of RiaSTAP

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for RiaSTAP(TM), the first and only treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

19 Jan 2009

The prevalence of gluten-sensitive enteropathy in iron-deficient anemia patients

Gluten sensitive enteropathy (GSE) is an autoimmune enteropathy due to food gluten intolerance in genetically predisposed people.

1 Jan 2009

FDA approves DNA test to measure hepatitis B viral load

The U.S. Food and Drug Administration today approved the first nucleic acid test for hepatitis B virus (HBV) that measures the amount of viral DNA (viral load) in a patient's blood. Assessing a patient's viral load provides health care professionals with a highly sensitive method for gauging the progress of antiviral therapy in patients with chronic HBV infections.

5 Sep 2008

Improved diagnosis of cutaneous leishmaniasis thanks to new techniques

Cutaneous leishmaniasis (CL) is a non-lethal disease but can have grave consequences for the patient.

25 Jan 2008

AACR's Sixth Annual Landon Awards recognize Richard Kolodner, Douglas Lowy and John Schiller

Scientists whose discoveries have led to fundamental advances in the science and treatment of cancer are the recipients of two prestigious international prizes offered by the Kirk A. and Dorothy P. Landon Foundation and the American Association for Cancer Research.

22 Mar 2007

Elite suppressors of HIV to change how scientists monitor spread of disease

Scientists at Johns Hopkins have found that 1 percent to 2 percent of those infected with HIV in Baltimore apparently suppress the virus to nearly undetectable levels on their own, confounding public health efforts to accurately monitor the pandemic's spread, now in its 20th year.

15 Aug 2006

Dual testing better for monitoring new cases of HIV

Johns Hopkins researchers will present results showing that tighter, dual testing standards work better for accurately distinguishing between new and old cases of HIV.

27 Feb 2005

International pharmaceutical industries and governments are failing to develop and produce AIDS medicines

International pharmaceutical industries and governments are failing to develop and produce AIDS medicines and diagnostic tools suited to children, claimed Médecins Sans Frontières at the XV International AIDS Conference in Bangkok.

15 Jul 2004